A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study.

Find People
Find Everything
About This Site
Edit My Profile
Login to Profiles
DIRECT2Experts
Help / FAQ

Announcement

You can now add alternative names! Click here to add other names that you've published under.

A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study.

Armstrong DK, Blessing JA, Rader J, Sorosky JI. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. Invest New Drugs. 2003 Nov; 21(4):453-7.

View in: PubMed

subject areas

Adult
Aged
Anemia
Bryostatins
Carcinoma, Squamous Cell
Confidence Intervals
Drug Administration Schedule
Female
Humans
Infusions, Intravenous
Lactones
Macrolides
Middle Aged
Neoplasm Recurrence, Local
Uterine Cervical Neoplasms

authors with profiles

Janet Rader